[1] 史云桃,蒋廷波.急性ST段抬高型心肌梗死患者恶性室性心律失常的危险因素研究[J].安徽医药,2018,22(11):2134-2137.
[2] JONES J P, RAMCHARAN T, CHAUDHARI M, et al. Ventricular Fibromas in Children, Arrhythmia Risk, and Outcomes: A Multicenter Study[J]. Heart Rhythm, 2018, 15(10): 1507-1512.
[3] 卢小伟.QT离散度、T波峰末间期及血清结缔组织生长因子水平对冠心病恶性心律失常的诊断价值分析[J].实用心脑肺血管病杂志,2017,25(11):59-62.
[4] 徐燕燕,潘泽意,周国勇.胺碘酮联合美托洛尔治疗潜在恶性心律失常的效果观察[J].中国医药,2016,11(11):1589-1592.
[5] NIREI K, NAKAMURA H, MATSUOKA S, et al. Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection[J]. Internal Med, 2017, 56(7): 787-790.
[6] 葛均波,徐永健.内科学 [M].8版.北京:人民卫生出版社,2013:102-105.
[7] KELLE A M, BOS J M, ETHERIDGE S P, et al. Cardiac Transplantation in Children and Adolescents with Long QT Syndrome[J]. Heart Rhythm, 2017, 14(8): 1182-1188.
[8] HEBBES C, THOMPSON J P. Drugs Acting on the Heart: Antiarrhythmics[J]. Anaesth Intens Care, 2018, 19(7): 370-374.
[9] NAGHI J J, SIEGEL R J. Medical Management of Hypertrophic Cardiomyopathy[J]. Rev Cardiovasc Med, 2019, 11(4): 202-217.
[10] AN Zhe, YANG Guang, LIU Xuanxuan, et al. New Progress in Understanding the Cellular Mechanisms of Anti-Arrhythmic Drugs[J]. Open Life Sci, 2018, 13(1): 335-339.
[11] BONNY A, NGANTCHA M, SCHOLTZ W, et al. Cardiac Arrhythmias in Africa: Epidemiology, Management Challenges, and Perspectives[J]. Journal of the American College of Cardiology, 2019, 73(1): 100-109.
[12] 王成钢,王春梅,艾辉,等.高敏C-反应蛋白对急性ST段抬高型心肌梗死早期恶性心律失常的预测价值[J].心肺血管病杂志,2019,38(6):589-592.
[13] BULENT G, GIUSEPPE B, GHEORGE-ANDREI D, et al. European Heart Rhythm Association (EHRA) Position Paper on Arrhythmia Management and Device Therapies in Endocrine Disorders, Endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS)[J]. EP Europace, 2018, 20(6): 895-896.
|